| Literature DB >> 28109136 |
Afsane Bahrami1, Forouzan Amerizadeh1, Soodabeh ShahidSales2, Majid Khazaei3, Majid Ghayour-Mobarhan2, Hamid Reza Sadeghnia1, Mina Maftouh4, Seyed Mahdi Hassanian5,4, Amir Avan4,2.
Abstract
Wnt/β-catenin pathway is one of the main/frequent dysregulated pathways in several tumor types, including colon cancer. Aberrant activation of this pathway is associated with cell proliferation, invasive behaviors, and cell resistance, suggesting its potential value as a therapeutic target in treatment of CRC. Several agents have been developed for targeting of this pathway (e.g, natural agents: curcumin, 3,3-diindolylmethane, phytoestrogen; Synthetic/small Wnt inhibitors: Rofecoxib; PRI-724, CWP232291; and monoclonal antibody against frizzled receptors, Vanituctumab). This review summarizes the current knowledge about the therapeutic potential of targeting Wnt pathway with particular emphasis on preclinical/clinical studies in treatment of colorectal cancer. J. Cell. Biochem. 118: 1979-1983, 2017.Entities:
Keywords: COLON CANCER; INHIBITOR; THERAPEUTIC TARGET; Wnt/β-CATENIN
Mesh:
Substances:
Year: 2017 PMID: 28109136 DOI: 10.1002/jcb.25903
Source DB: PubMed Journal: J Cell Biochem ISSN: 0730-2312 Impact factor: 4.429